Commission Decision of 28 August 2007 concerning measures to prevent the spread of highly pathogenic avian influenza to other captive birds kept in zoos and approved bodies, institutes or centres in the Member States (notified under document number C(2007) 3987) (Text with EEA relevance) (2007/598/EC)

ANNEX I U.K. Criteria and risk factors to be considered when applying the measures set out in Article 3 in zoos and approved bodies, institutes or centres

1. Location of zoos and approved bodies, institutes or centres along migratory flyways of birds, in particular if proceeding from countries where outbreaks of highly pathogenic avian influenza have occurred, taking into account the serotype detected and the likelihood of wild birds having been affected. U.K.

2. Distance of zoos and approved bodies, institutes or centres from wetlands and water areas such as ponds, swamps, lakes or rivers where migratory waterfowl may gather. U.K.

3. Location of zoos and approved bodies, institutes or centres in areas of a high density of migratory birds, particularly waterfowl. U.K.

ANNEX II U.K.

Requirements for the use of preventive vaccination as referred to in Αrticle 4

1.	Extent of the vaccination to be carried out	The vaccination against avian influenza shall only be carried out in birds kept in zoos and approved bodies, institutes or centres. The competent authority shall keep lists of zoos, approved bodies, institutes or centres for a period of at least five years from the date of such vaccination.
2.	Bird species to be vaccinated	The competent authority shall be notified of a list of birds to be vaccinated together with the individual identification and keep it for at least five years from the date of the vaccination.
3.	Duration of vaccination	(a) All birds to be vaccinated in zoos and approved bodies institutes or centres shall be vaccinated as quickly as possible. (b) Offspring, newly introduced birds and birds for which an insufficient immune response has been demonstrated must also be vaccinated. (c) Annual re-vaccination is recommended to maintain bird immunity.
4.	Specific requirements for movements of birds	(a) Vaccinated birds kept in approved bodies, institutes or centres including zoos approved in accordance with Directive 92/65/EEC where vaccination is carried out may be moved to approved bodies, institutes or centres in F1 ... Member States provided that they meet the requirements set out in this Decision and are accompanied by a health certificate [F2 where] the following must be certified: ‘Birds conform to Decision 2007/598/EC were vaccinated against avian influenza on … (date) with vaccine … (name)’. (b) Vaccinated birds kept in zoos that are not approved in accordance with Directive 92/65/EEC where vaccination is carried out may be moved to F3 ... Member States after authorisation by the Member State of destination provided that they meet the requirements set out in this Decision and are accompanied by a health certificate [F4 that includes the following words].: ‘Birds conform to Decision 2007/598/EC and vaccinated against avian influenza on … (date) with vaccine … (name)’. (c) When vaccination of birds kept in zoos, approved bodies, institutes or centres is not longer applied, the conditions for movements laid down in points (a) and (b) shall be maintained for a period of 12 months from the date of the vaccination of the last bird.
5.	Special identification and special registration of the vaccinated birds	Vaccinated birds must be individually identifiable and the identity records of these birds must be clearly annotated accordingly. An indelible identification of the other captive birds indicating that they have been vaccinated shall be applied at the time of vaccination wherever possible.
6.	Execution of the vaccination campaign	(a) Vaccination shall be carried out under the supervision of a veterinarian and necessary measures must be in place to avoid possible spread of virus. (b) A written record on the number of vaccinated birds and the number of vaccine doses used shall be communicated to the competent authority after vaccination is carried out and thereafter on a monthly basis, if further birds as referred to in point 3(b) are vaccinated. (c) Wherever possible blood samples from 10 % of the birds shall be taken prior to and at least 30 days from the date of each vaccination for serological testing for avian influenza. A record of the test results must be kept for at least five years from the date of vaccination.
7.	Vaccine to be used	The inactivated vaccine to be used shall be suitably formulated and be effective against highly pathogenic avian influenza virus of subtype H5 or H7 or both. It shall be used in accordance with the instructions of the manufacturer and/or the veterinary authorities.

Textual Amendments

F1 Word in Annex 2 item 4(a) omitted (31.12.2020) by virtue of The Exotic Disease (Amendment etc.) (EU Exit) Regulations 2018 (S.I. 2018/1410), regs. 1, 13(8)(a)(i); 2020 c. 1, Sch. 5 para. 1(1)

F2 Word in Annex 2 item 4(a) substituted (31.12.2020) by The Exotic Disease (Amendment etc.) (EU Exit) Regulations 2018 (S.I. 2018/1410), regs. 1, 13(8)(a)(ii); 2020 c. 1, Sch. 5 para. 1(1)

F3 Word in Annex 2 item 4(b) omitted (31.12.2020) by virtue of The Exotic Disease (Amendment etc.) (EU Exit) Regulations 2018 (S.I. 2018/1410), regs. 1, 13(8)(b)(i); 2020 c. 1, Sch. 5 para. 1(1)

F4 Words in Annex 2 item 4(b) substituted (31.12.2020) by The Exotic Disease (Amendment etc.) (EU Exit) Regulations 2018 (S.I. 2018/1410), regs. 1, 13(8)(b)(ii); 2020 c. 1, Sch. 5 para. 1(1)

F5 ANNEX III U.K.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Textual Amendments

F5 Annex 3 omitted (31.12.2020) by virtue of The Exotic Disease (Amendment etc.) (EU Exit) Regulations 2018 (S.I. 2018/1410), regs. 1, 13(9); 2020 c. 1, Sch. 5 para. 1(1)

ANNEX IV U.K.

Reporting model for the implementation of the approved preventive vaccination plans referred to in article 6(2)

General information
Country	Zoo	Vaccine	Route(specify if different in different species)	Weight — Dose regime used(Actual/estimated/average weight of species)	Vaccine interval	Interval from last vaccination to post-vaccination blood collection

HI serum antibody titre
English name/local name	Latin name	Taxonomic Order	Individual identification	VaccineDose (ml)	Pre-vacc	Post-1st vacc	Post-2nd vacc

Adverse Individual effects		Mortality
Local	general	Direct(catching/handling)	Delayed(specify cause of death)

Information required from the Laboratory
Virus strain of vaccine	Antigens (virus strains) used in HI test	Cut-off or end-titre point used as a measure of vaccine efficacy	Reference serum used	(reference to)Methodology